NeOnc reports Q1 net loss $8.8M; NEO212 Phase 1 complete, NEO100 interim data Aug 2026

NEONC TECHNOLOGIES HOLDINGS, INC.

2026-Q1 EPS reported -$0.38 vs consensus -$0.22 ▼ miss (-69.3%)

Net loss $8.8M ($0.38/diluted) vs $32.3M ($1.78) in Q1 2025; G&A down to $489K, R&D up to $1.29M.
Cash $138,601 at Mar 31; $10M PIPE from Cinctive Capital and $10M undrawn credit line fund ops into Sep 2026.
NEO212 Phase 1 complete, RP2D set at 610 mg; FDA End-of-Phase 1 meeting planned for potential registrational Phase 2.
NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected August 2026.
Appointed David Choi as CAO; CEO Amir Heshmatpour purchased >$500k of NTHI shares in open market.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.